Chronic Kidney Disease Is Associated with Increased Plasma Levels of Fibroblast Growth Factors 19 and 21
© 2019 The Author(s) Published by S. Karger AG, Basel..
BACKGROUND: Chronic kidney disease (CKD) is the result of a reduced number of nephrons, in which adipose tissue and its metabolites play a significant role. Fibroblast growth factors, FGF19 and FGF21, are involved in lipid and carbohydrate metabolism. The aim of the study was to examine the concentrations of FGF19 and FGF21 in patients with CKD, as well as the correlation between FGF19 and FGF21 and selected biochemical parameters.
MATERIALS AND METHODS: The study included 178 subjects: 52 patients with CKD in stages 2-4, without haemodialysis (CKD), 47 haemodialysed patients with CKD (HD), 56 patients with CKD after a renal transplantation (Tx) and 23 healthy subjects as the control group (C).
RESULTS: The highest FGF19 serum concentrations were observed in CKD patients and the lowest were observed in the Tx group. Patients in the CKD group had significantly higher serum FGF21 concentrations. There were negative correlations between FGF19 and glomerular filtration rate (GFR), as well as high-density lipoprotein cholesterol levels in patients after kidney transplantation. Negative correlations were also found between serum FGF21 concentrations and GFR in patients after Tx, while positive correlations were observed between FGF21 concentrations and lean body mass in the CKD group, body mass index and total cholesterol in the HD group.
CONCLUSIONS: Our results suggest that increased concentrations of FGF19 and FGF21 in patients with CKD may be associated with the metabolism of lipids and carbohydrates. Our results also indicate that haemodialysis and transplantation results in the reduction of FGF19 and FGF21 concentrations in patients with CKD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Kidney & blood pressure research - 44(2019), 5 vom: 24., Seite 1207-1218 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marchelek-Myśliwiec, Małgorzata [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.03.2020 Date Revised 03.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000502647 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302208658 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302208658 | ||
| 003 | DE-627 | ||
| 005 | 20231225110234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000502647 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1007.xml |
| 035 | |a (DE-627)NLM302208658 | ||
| 035 | |a (NLM)31614355 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marchelek-Myśliwiec, Małgorzata |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic Kidney Disease Is Associated with Increased Plasma Levels of Fibroblast Growth Factors 19 and 21 |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2020 | ||
| 500 | |a Date Revised 03.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 The Author(s) Published by S. Karger AG, Basel. | ||
| 520 | |a BACKGROUND: Chronic kidney disease (CKD) is the result of a reduced number of nephrons, in which adipose tissue and its metabolites play a significant role. Fibroblast growth factors, FGF19 and FGF21, are involved in lipid and carbohydrate metabolism. The aim of the study was to examine the concentrations of FGF19 and FGF21 in patients with CKD, as well as the correlation between FGF19 and FGF21 and selected biochemical parameters | ||
| 520 | |a MATERIALS AND METHODS: The study included 178 subjects: 52 patients with CKD in stages 2-4, without haemodialysis (CKD), 47 haemodialysed patients with CKD (HD), 56 patients with CKD after a renal transplantation (Tx) and 23 healthy subjects as the control group (C) | ||
| 520 | |a RESULTS: The highest FGF19 serum concentrations were observed in CKD patients and the lowest were observed in the Tx group. Patients in the CKD group had significantly higher serum FGF21 concentrations. There were negative correlations between FGF19 and glomerular filtration rate (GFR), as well as high-density lipoprotein cholesterol levels in patients after kidney transplantation. Negative correlations were also found between serum FGF21 concentrations and GFR in patients after Tx, while positive correlations were observed between FGF21 concentrations and lean body mass in the CKD group, body mass index and total cholesterol in the HD group | ||
| 520 | |a CONCLUSIONS: Our results suggest that increased concentrations of FGF19 and FGF21 in patients with CKD may be associated with the metabolism of lipids and carbohydrates. Our results also indicate that haemodialysis and transplantation results in the reduction of FGF19 and FGF21 concentrations in patients with CKD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adipose tissue | |
| 650 | 4 | |a Body composition | |
| 650 | 4 | |a Chronic kidney disease | |
| 650 | 4 | |a Fibroblast growth factor 19 | |
| 650 | 4 | |a Fibroblast growth factor 21 | |
| 650 | 4 | |a Haemodialysis | |
| 650 | 4 | |a Kidney transplantation | |
| 650 | 7 | |a FGF19 protein, human |2 NLM | |
| 650 | 7 | |a fibroblast growth factor 21 |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factors |2 NLM | |
| 650 | 7 | |a 62031-54-3 |2 NLM | |
| 700 | 1 | |a Dziedziejko, Violetta |e verfasserin |4 aut | |
| 700 | 1 | |a Nowosiad-Magda, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Dołęgowska, Katarzyna |e verfasserin |4 aut | |
| 700 | 1 | |a Dołęgowska, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Pawlik, Andrzej |e verfasserin |4 aut | |
| 700 | 1 | |a Safranow, Krzysztof |e verfasserin |4 aut | |
| 700 | 1 | |a Wiśniewska, Magda |e verfasserin |4 aut | |
| 700 | 1 | |a Stępniewska, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Domański, Maciej |e verfasserin |4 aut | |
| 700 | 1 | |a Ciechanowski, Kazimierz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney & blood pressure research |d 1998 |g 44(2019), 5 vom: 24., Seite 1207-1218 |w (DE-627)NLM087871165 |x 1423-0143 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2019 |g number:5 |g day:24 |g pages:1207-1218 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000502647 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2019 |e 5 |b 24 |h 1207-1218 | ||